Cover Image

The silent and dangerous inequity around access to COVID-19 testing: a call to action

COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92·3% [95% CI: 85·7‒95·8]) against SARS-CoV-2 in clinical trials. This study aimed to estimate Abdala's real-world vaccine e...

Full description

Saved in:
Bibliographic Details
Main Authors: Batista, Carolina (Author) , Hotez, Peter (Author) , Amor, Yanis Ben (Author) , Kim, Jerome H (Author) , Kaslow, David (Author) , Lall, Bhavna (Author) , Ergonul, Onder (Author) , Figueroa, J Peter (Author) , Gursel, Mayda (Author) , Hassanain, Mazen (Author) , Kang, Gagandeep (Author) , Larson, Heidi (Author) , Naniche, Denise (Author) , Sheahan, Timothy (Author) , Wilder-Smith, Annelies (Author) , Shoham, Shmuel (Author) , Sow, Samba O (Author) , Yadav, Prashant (Author) , Strub-Wourgaft, Nathalie (Author) , Loveday, Sarah-Jane (Author) , Hannay, Emma (Author) , Bottazzi, Maria Elena (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2022
In: EClinicalMedicine
Year: 2022, Volume: 43, Pages: 1-4
ISSN:2589-5370
DOI:10.1016/j.eclinm.2021.101230
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.eclinm.2021.101230
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2589537021005113
Get full text
Author Notes:Carolina Batista, Peter Hotez, Yanis Ben Amor, Jerome H. Kim, David Kaslow, Bhavna Lall, Onder Ergonul, J. Peter Figueroa, Mayda Gursel, Mazen Hassanain, Gagandeep Kang, Heidi Larson, Denise Naniche, Timothy Sheahan, Annelies Wilder-Smith, Shmuel Shoham, Samba O. Sow, Prashant Yadav, Nathalie Strub-Wourgaft, Sarah-Jane Loveday, Emma Hannay, and Maria Elena Bottazzi
Description
Summary:COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92·3% [95% CI: 85·7‒95·8]) against SARS-CoV-2 in clinical trials. This study aimed to estimate Abdala's real-world vaccine effectiveness (VE). - This retrospective cohort study in Havana analyzed Cuban Ministry of Public Health databases (May 12-August 31, 2021) to assess VE in preventing severe illness and death from COVID-19 (primary outcomes). Cox models accounting for time-varying vaccination status and adjusting by demographics were used to estimate hazard ratios. A subgroup analysis by age group and a sensitivity analysis including a subgroup of tested persons (qRT-PCR) were conducted. Daily cases and deaths were modelled accounting for different VE. - The study included 1 355 638 persons (Mean age: 49·5 years [SD: 18·2]; 704 932 female [52·0%]; ethnicity data unavailable): 1 324 vaccinated (partially/fully) and 31 433 unvaccinated. Estimated VE against severe illness was 93·3% (95% CI: 92·1-94·3) in partially- vaccinated and 98·2% (95% CI: 97·9-98·5) in fully-vaccinated and against death was 94·1% (95% CI: 92·5-95·4) in partially-vaccinated and 98·7% (95% CI: 98·3-99·0) in fully-vaccinated. VE exceeded 92·0% in all age groups. Daily cases and deaths during the study period corresponded to a VE above 90%, as predicted by models. - The Cuban Abdala protein subunit vaccine was highly effective in preventing severe illness and death from COVID-19 under real-life conditions. - Cuban Ministry of Public Health. Genetic Engineering and Biotechnology Centre.
Item Description: Version des Artikels 13 December 2021
Gesehen am 05.10.2022
Physical Description:Online Resource
ISSN:2589-5370
DOI:10.1016/j.eclinm.2021.101230

Similar Items